H124: Focus on next steps for diabetes and obesity
Arecor’s H124 interim results reaffirm that the focus remains on advancing the key diabetes and obesity franchise. This includes: (1) next development steps for lead asset AT278, a unique ultra-rapid and ultra-concentrated insulin that could enable next-generation insulin pump delivery systems, following best-case Phase I data in overweight and obese Type II diabetes (September 2024 Update); (2) potential for first insights into the early-stage oral GLP-1 for obesity, with initial formulation development successfully completed and data from non-clinical PK (pharmacokinetic) studies expected H125; and (3) profile raising through attendance at key diabetes conferences, also enabling deepening of industry relationships, such as the existing collaboration with Medtronic for a thermostable insulin for implantable pump delivery.
Arecor Therapeutics: Trinity Delta Lighthouse
Sep 26, 2024Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.